^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
Source:
Title:
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Excerpt:
...Methylguanine-DNA methyltransferase (MGMT) status`PDL1 expression in tumor`Peripheral T-cell activation`T-cell infiltrate in tumor`Tryptophan metabolites...
Trial ID:
Source:
Title:
Pembrolizumab for Newly Diagnosed Glioblastoma
Excerpt:
...Response rates using (i)RANO (immunotherapy response assessment in neuro-oncology) criteria`Progression-free survival (PFS) at 6 and 12 months`Time to treatment failure (TTF)`Health-related Quality of life (HRQol)`Correlation of programmed cell death (PD-1) ligand 1 (PD-L1) expression levels with response to treatment and outcome...
Less C2 evidence
Source:
Title:
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial
Published date:
01/26/2021
Excerpt:
Adult patients with PD‐L1–positive tumors were enrolled in the recurrent glioblastoma cohort of the multicohort, phase 1b KEYNOTE‐028 study (ClinicalTrials.gov identifier, NCT02054806) and received pembrolizumab...Progression‐free survival (median, 2.8 months; 95% CI, 1.9‐8.1 months) rate at 6 months was 37.7%, and the overall survival (median, 13.1 months; 95% CI, 8.0‐26.6 months) rate at 12 months was 58%.
DOI:
10.1002/cncr.33378
Trial ID: